이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CellaVision 과거 수익 실적

과거 기준 확인 5/6

CellaVision은 연평균 6.3%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 증가했으며, 연간 17%였습니다. 매출은 연평균 10.6%의 비율로 증가했습니다. CellaVision의 자기자본이익률은 18.6%이고 순이익률은 19.9%입니다.

주요 정보

7.2%

수익 성장률

7.2%

EPS 성장률

Medical Equipment 산업 성장	6.2%
매출 성장률	10.4%
자기자본 수익률	19.6%
순이익	20.0%
다음 실적 업데이트	24 Oct 2024

최근 과거 실적 업데이트

Recent updates

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 24

CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price

Apr 09

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Mar 28

CellaVision's (STO:CEVI) Dividend Will Be SEK2.25

Mar 14

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Feb 29

After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar

Feb 16

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Feb 12

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business

Dec 13

Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Sep 14

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Aug 22

CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return

Jun 17

CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's

May 07

Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)

Apr 19

CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25

Apr 05

CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year

Mar 04

CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be

Feb 11

Is CellaVision (STO:CEVI) A Risky Investment?

Jan 13

Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?

Dec 13

CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly

Sep 23

CellaVision (STO:CEVI) May Have Issues Allocating Its Capital

Aug 16

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Aug 02

We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease

Jun 27

What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?

May 31

CellaVision (STO:CEVI) Could Easily Take On More Debt

Apr 28

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Apr 07

수익 및 비용 분석

CellaVision 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:CEVI 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	726	145	217	83
31 Mar 24	708	141	213	84
31 Dec 23	677	130	213	83
30 Sep 23	629	112	202	83
30 Jun 23	602	97	196	91
31 Mar 23	616	99	196	91
31 Dec 22	639	118	191	89
30 Sep 22	651	126	194	86
30 Jun 22	642	142	186	72
31 Mar 22	594	135	174	67
31 Dec 21	566	125	165	64
30 Sep 21	532	114	160	61
30 Jun 21	488	101	150	54
31 Mar 21	471	98	147	52
31 Dec 20	471	89	152	51
30 Sep 20	490	85	159	54
30 Jun 20	498	89	165	59
31 Mar 20	492	92	163	60
31 Dec 19	462	99	150	56
30 Sep 19	423	104	135	53
30 Jun 19	412	104	131	48
31 Mar 19	391	97	124	43
31 Dec 18	365	89	120	39
30 Sep 18	330	76	114	33
30 Jun 18	307	67	109	30
31 Mar 18	294	63	106	27
31 Dec 17	309	70	106	27
30 Sep 17	306	70	101	28
30 Jun 17	313	78	97	28
31 Mar 17	300	75	92	30
31 Dec 16	265	60	86	29
30 Sep 16	254	57	85	29
30 Jun 16	260	66	82	27
31 Mar 16	246	55	82	28
31 Dec 15	239	53	82	27
30 Sep 15	250	49	84	29
30 Jun 15	223	30	82	28
31 Mar 15	226	34	83	25
31 Dec 14	217	31	80	23
30 Sep 14	209	33	73	19
30 Jun 14	207	36	70	17
31 Mar 14	189	26	67	18
31 Dec 13	180	19	66	21
30 Sep 13	165	3	67	21

양질의 수익: CEVI 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: CEVI 의 현재 순이익 이익률 (19.9%) 작년보다 높습니다 (16.1%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: CEVI 의 수입은 지난 5년 동안 매년 6.3% 씩 증가했습니다.

성장 가속화: 지난 1년간 CEVI 의 수익 증가율( 42.4% )은 연간 평균( 6.3% 초과합니다. ).

수익 대 산업: 지난 1년간 CEVI 수익 증가율( 50.2% )은 Medical Equipment 업계 44.1% 초과했습니다.

CellaVision 과거 수익 실적

과거 기준 확인 5/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Recent updates

Now 23% undervalued

Founder & Director recently sold kr27m worth of stock

CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Is CellaVision (STO:CEVI) A Risky Investment?

Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 15%

Upcoming dividend of kr2.25 per share

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25

CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

CellaVision's (STO:CEVI) Dividend Will Be SEK2.25

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Now 22% undervalued

Now 21% undervalued

After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar

CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25

Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Dividend of kr2.25 announced

Price target increased by 21% to kr232

Consensus EPS estimates fall by 13%

Investor sentiment improves as stock rises 30%

Now 21% undervalued

CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Price target decreased by 8.0% to kr203

Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)

Price target increased by 8.6% to kr220

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

Investor sentiment deteriorates as stock falls 17%

CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return

CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's

Cellavision AB (Publ) Approves Dividend, Payable on May 12, 2023

Upcoming dividend of kr2.25 per share at 1.3% yield

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)

Price target decreased by 11% to kr223

Full year 2022 earnings: EPS and revenues miss analyst expectations

CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25

Now 22% undervalued after recent price drop

CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year

Now 21% undervalued after recent price drop

Founder & Director recently bought kr63k worth of stock

CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Cellavision AB (Publ) Proposes Dividend for 2022

Now 23% undervalued

Investor sentiment improves as stock rises 15%

Is CellaVision (STO:CEVI) A Risky Investment?

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?

Now 21% undervalued after recent price drop

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Price target decreased to kr253

Investor sentiment deteriorated over the past week